Abstract
Malignant gliomas are the most common primary brain tumors. Despite efforts to find effective treatments, these tumors remain incurable. The failure of malignant gliomas to respond to conventional cancer therapies may reflect the unique biology of these tumors, underscoring the need for new approaches in their investigation. Recently, progress has been made in characterization of the molecular pathogenesis of glioblastoma using a developmental neurobiological perspective, by exploring the role of signaling pathways that control the differentiation of neural stem cells along the glial lineage. The transcription factor STAT3, which has an established function in neural stem cell and astrocyte development, has been found to play dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. These findings establish a novel developmental paradigm in the study of glioblastoma pathogenesis and provide the rationale for patient-tailored therapy in the treatment of this devastating disease.
Current Molecular Medicine
Title: STAT3 Regulation of Glioblastoma Pathogenesis
Volume: 9 Issue: 5
Author(s): Nuria de la Iglesia, Sidharth V. Puram and Azad Bonni
Affiliation:
Abstract: Malignant gliomas are the most common primary brain tumors. Despite efforts to find effective treatments, these tumors remain incurable. The failure of malignant gliomas to respond to conventional cancer therapies may reflect the unique biology of these tumors, underscoring the need for new approaches in their investigation. Recently, progress has been made in characterization of the molecular pathogenesis of glioblastoma using a developmental neurobiological perspective, by exploring the role of signaling pathways that control the differentiation of neural stem cells along the glial lineage. The transcription factor STAT3, which has an established function in neural stem cell and astrocyte development, has been found to play dual tumor suppressive and oncogenic roles in glial malignancy depending on the mutational profile of the tumor. These findings establish a novel developmental paradigm in the study of glioblastoma pathogenesis and provide the rationale for patient-tailored therapy in the treatment of this devastating disease.
Export Options
About this article
Cite this article as:
la Iglesia de Nuria, Puram V. Sidharth and Bonni Azad, STAT3 Regulation of Glioblastoma Pathogenesis, Current Molecular Medicine 2009; 9 (5) . https://dx.doi.org/10.2174/156652409788488739
DOI https://dx.doi.org/10.2174/156652409788488739 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets Snake Venom L-Amino Acid Oxidases: Some Consideration About their Functional Characterization
Protein & Peptide Letters Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Gene Selection in Multi-class Imbalanced Microarray Datasets Using Dynamic Length Particle Swarm Optimization
Current Bioinformatics Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology FOXM1-Dependent Transcriptional Regulation of EZH2 Induces Proliferation and Progression in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets Advances in Helper-Dependent Adenoviral Vector Research
Current Gene Therapy <i>Lophira alata</i> Suppresses Phorbol Ester-Mediated Increase in Cell Growth via Inhibition of Protein Kinase C-α/Akt in Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry Animal Models for the Evaluation of Theranostic Radiopharmaceuticals
Current Radiopharmaceuticals CPP-Based Bioactive Drug Delivery to Penetrate the Blood-Brain Barrier: A Potential Therapy for Glioblastoma Multiforme
Current Drug Targets CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Brain Targeting of siRNA via Intranasal Pathway
Current Pharmaceutical Design Mechanisms of Immune Modulation by Mesenchymal Stromal Cells and Clinical Translation
Current Molecular Medicine